congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
I-DXd
WCLC 2023 | September 9-12, 2023
A phase 2 study of ifinatamab deruxtecan (I-DXd; DS-7300) in patients with previously treated ES-SCLC
Poster
Dato-DXd
WCLC 2023 | September 9-12, 2023
AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as first-line treatment of advanced/metastatic non-small-cell lung cancer
Poster
HER3-DXd
WCLC 2023 | September 9-12, 2023
Clinical outcomes of real-world treatment for metastatic EGFRm NSCLC after osimertinib and platinum-based chemotherapy
Oral
Dato-DXd
WCLC 2023 | September 9-12, 2023
Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/metastatic NSCLC: Initial results from the phase 1b TROPION-Lung04 study
Poster
HER3-DXd
WCLC 2023 | September 9-12, 2023
HER3 expression in archived tissue samples from patients with NSCLC across various genomic subtypes and characteristics
Oral
I-DXd
WCLC 2023 | September 9-12, 2023
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: A subgroup analysis of a phase 1/2 study
Poster
HER3-DXd
WCLC 2023 | September 9-12, 2023
Metastatic non-small cell lung cancer with EGFR mutations: Treatment patterns and outcomes from a systematic literature review
Oral
HER3-DXd
WCLC 2023 | September 9-12, 2023
Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01
Mini-Oral
T-DXd
WCLC 2023 | September 9-12, 2023
Trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer: Primary results of DESTINY-Lung02
Poster
Dato-DXd
WCLC 2023 | September 9-12, 2023
TROPION-Lung08: Datopotamab deruxtecan plus pembrolizumab in untreated advanced/metastatic non-small cell lung cancer (NSCLC)